Sanofi India (500674) Q3 2024 earnings summary

Executive summary

• Net sales grew 8% year-over-year for Q3 2024, driven by strong diabetes portfolio performance and new product launches, notably SoliquaⓇ.

• Operating profit increased 6% year-over-year, with Q3 2024 profit from operations at INR 110 crores versus INR 104 crores in Q3 2023.

• The demerger of the Consumer Healthcare business into Sanofi Consumer Healthcare India Limited was effective June 1, 2024; results for this segment are now presented as discontinued operations.

Financial highlights

• Standalone revenue from operations for Q3 2024 was INR 5,240 million, up from INR 4,907 million in Q3 2023.

• Standalone profit for the period (continuing and discontinued) was INR 1,034 million in Q3 2024, compared to INR 1,522 million in Q3 2023.

• Consolidated revenue from operations for Q3 2024 was INR 5,240 million, with consolidated profit for the period at INR 1,032 million.

• Exceptional items for the nine months ended September 30, 2024, included a personnel separation cost of INR 457 million.

• Basic and diluted EPS (continuing and discontinued) for Q3 2024 was INR 44.90 (standalone) and INR 44.81 (consolidated).

Outlook and guidance

• Recent partnerships in CNS and cardiovascular segments are expected to accelerate brand reach and expansion.

• The company is optimistic about the future, citing momentum from new launches and positive initial results from partnerships.